CMN Weekly (8 November 2024) - Your Weekly CRISPR...
CMN Weekly
Nov. 8, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Verve Therapeutics
Main focus: Gene editing for the treatment of genetic cardiovascular diseases
Company stage: Pre-clinical
Diseases: Heterozygous familial hypercholesterolemia, familial hypercholesterolemia
Genome editing technology: Base editing, CRISPR-Cas9, CRISPR-Cas12a
Funding stage: Public (NASDAQ:VERV)
Location: Cambridge, MA, USA
Website: https://www.vervetx.com/
Pipeline: https://www.vervetx.com/pipeline/
Partners: Beam Therapeutics
Verve Therapeutics is a pre-clinical stage gene-editing company that focuses on developing novel therapies for genetic cardiovascular diseases. The company holds multiple licenses from The Broad Institute and has also licensed base-editing technology from Beam Therapeutics. The company is initially focusing on PCSK9 and ANGPTL3 as targets.
Tags
Related News and Updates
Clinical Trials
IND Enabling
Phase I
Phase II
Phase III
Familial Hypercholesterolemia, HeFH, or Premature Coronary Artery Disease, CAD, (NCT06164730)
Sponsors:
Verve Therapeutics, Inc.
Sponsors:
Verve Therapeutics, Inc.
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
